Bulletin from Moberg Pharma’s AGM on May 16th, 2023

Bulletin from Moberg Pharma’s AGM on May 16^th, 2023

STOCKHOLM, May 16^th, 2023. Moberg Pharma AB (publ)’s (“Moberg Pharma” or the “Company”) Annual General Meeting took place today. The Annual General Meeting resolved in accordance with the Nomination Committee’s and Board of Directors’ proposals as set out below.

Adoption of the income statements and the balance sheets
The Annual General Meeting approved the income statements and the balance sheets for the fiscal year 2022.

The Annual General Meeting resolved, in accordance with the proposal of the Board of Directors that no dividend should be paid for the fiscal year 2022.

The Annual General Meeting discharged the Board members and the Chief Executive Officer from liability for the fiscal year 2022.

Board of Directors
In accordance with the proposal of the Nomination Committee, the Annual General Meeting resolved that the Board of Directors shall consist of four persons and no deputies.

The Annual General Meeting resolved, in accordance with the proposal of the Nomination Committee, on re-election of Nikolaj Sörensen, Kerstin Valinder Strinnholm and Anders Lundmark as well as election of Håkan Wallin as board members for a period until the end of the next Annual General Meeting. Kerstin Valinder Strinnholm was elected Chairman of the Board for the period until the end of the next Annual General Meeting.

The Annual General Meeting resolved, in accordance with the proposal of the Nomination Committee, that an unchanged aggregate annual fee of SEK 870,000 shall be paid to the Board members, of which SEK 360,000 to the Chairman of the Board of Directors and SEK 170,000 to each of the other Board members elected by the General Meeting.

Fees to the Auditors, for a period until the end of the next Annual General Meeting, are to be paid as per approved invoice.

Nomination Committee
The Annual General Meeting resolved, in accordance with the proposal of the Nomination Committee, that the Company shall have a Nomination Committee consisting of three members. The Nomination Committee shall comprise one representative of each of the two largest shareholders or owner groups in the Company in terms of votes as per September 29^th, 2023, besides the Chairman of the Board of Directors.

Principles for remuneration
The Annual General Meeting resolved to approve the Board of Director’s proposal for principles of remuneration to senior executives in Moberg Pharma.

Remuneration report
The Annual General Meeting resolved to approve the Board of Director’s remuneration report in accordance with Chapter 8, Section 53a of the Swedish Companies Act.

Reverse share split and amendments to the articles of association
The Annual General Meeting resolved, in accordance with the Board of Directors' proposal on a reverse share split and amendments of the limits for the share capital and the number of shares in the articles of association. The reverse share split will be carried out by ten (10) existing shares consolidating into one (1) share (Sw: Sammanläggning 1:10). If a shareholder's holding of shares does not correspond to a full number of shares, the excessive shares will pass to the Company at the record date of the reverse share split. Excessive share will thereafter be sold by the Company at the Company's expense, whereby concerned shareholders will receive their part of the sales proceeds. The Annual General Meeting also resolved to authorize the Board of Directors to determine the record date for the reverse share split. Following the reverse share split, the number of shares in the Company will decrease from 100,859,335 to 10,085,933. The proposed reverse share split will result in a change of the share’s quotient value from SEK 0.1 to approximately
SEK 1.

The resolution to amend the limits of the share capital in the articles of association means that the share capital shall be not less than SEK 10,000,000 and not more than SEK 40,000,000 (previously not less than SEK 4,000,000 and not more than SEK 16,000,000). The resolution to amend the limits of the number of shares in the articles of association means that the number of shares shall be not less than 10,000,000 and not more than 40,000,000 (previously not less than 40,000,000 and not more than 160,000,000).

Implementation of LTI 2023
The Annual General Meeting also resolved to approve the Board of Director’s proposal to implement a long-term incentive program, including transfer of up to 187,000 ordinary shares to the participants and other hedging arrangements in respect of the program, including authorization for the Board of Directors to resolve on a directed issue and repurchase of up to 187,000 class C shares.

Authorization to issue shares
The Annual General Meeting resolved, in accordance with the proposal of the Board of Directors, to authorize the Board of Directors to, within the scope of the articles of association, with or without deviation from the shareholders’ pre-emptive rights, on one or several occasions during the period until the next Annual General Meeting, resolve to increase the Company’s share capital by issuing new shares in the Company. The total number of shares issued in accordance with this authorisation may be equivalent to a maximum of twenty (20) per cent of the shares in the Company at the first time the Board of Directors makes a resolution by virtue of the authorization.

Minutes from the meeting and complete resolutions
The minutes from the Annual General Meeting will be made available at the Company and on the Company’s website, www.mobergpharma.com.

For additional information, please contact:
Anna Ljung, CEO, telephone: +46 70 766 60 30, e-mail: anna.ljung@mobergpharma.se
Mark Beveridge, Vice President Finance, telephone: +46 76 805 82 88, e-mail: mark.beveridge@moberpharma.se

About this information
The information was submitted for publication at 6 p.m. CEST on May 16^th 2023 through the contact persons above.

About Moberg Pharma,  www.mobergpharma.com
Moberg Pharma AB (publ) is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The Company’s main asset, MOB-015, is a novel topical treatment for onychomycosis. Data from phase 3 clinical trials in more than 800 patients for MOB-015 indicate that the product has the potential to become the future market leader in onychomycosis. Moberg Pharma has agreements with commercial partners in place in Europe and Canada, among others, and the Company's goal is to receive its first market approval in 2023. Moberg Pharma is headquartered in Stockholm and the Company’s shares are listed on the Small Cap list of the Nasdaq Stockholm (OMX: MOB).